



Conoscere e Curare il Cuore 2016


LA GENETICA PER PREDIRE IL RISCHIO DI MORTE IMPROVVISA

Diego Ardissino

*Unità Operativa di Cardiologia
Azienda Ospedaliero - Universitaria di Parma*



Annual incidence of SCD by age-group




Modified by Maron BJ et al., *Circulation* 2009 119:1085-1092



Divisione di Cardiologia
Parma

Incidence of SCD Athletes



Modified by Maron BJ et al., *Circulation* 2009 119:1085-1092



Divisione di Cardiologia
Parma

Usefulness of Cardiovascular Genetic

- **Intermediate Phenotype**
- **Risk stratification of well known phenotype**
- **Molecular Autopsy**
- **Family Screening**



Intermediate Phenotype

LA STAMPA

07/11/2003

IL NUOTATORE NOVARESE E' STATO BLOCCATO PER IL SOSPETTO DI UNA GRAVE PATOLOGIA CARDIACA

Le paure di Fioravanti «Ditemi che cosa ho»

«Il medico che mi ha visitato non mi ha spiegato nulla, poi ha parlato dei miei problemi a una radio. Se sono davvero malato, 3 mesi di stop non fanno senso: meglio smettere subito. Io dispiro? Abbiate pietà»

Intervista
Fioravanti

Un nuotatore che si è visto bloccare la carriera da una grave patologia cardiaca. Fioravanti, 25 anni, è un atleta di alto livello. Ha vinto diverse medaglie in gare internazionali. Ma da qualche tempo si sente male. Ha deciso di fermarsi per un periodo di tempo. Ma il medico che lo ha visitato non gli ha spiegato nulla. Fioravanti è disperato. Vuole sapere cosa ha. «Ditemi che cosa ho», dice. «Se sono davvero malato, 3 mesi di stop non fanno senso: meglio smettere subito. Io dispiro? Abbiate pietà».



«Voglio solo sapere qual è la mia malattia?»




Usefulness of Cardiovascular Genetic

- Intermediate Phenotype
- **Risk stratification of well known phenotype**
- Molecular Autopsy
- Family Screening




Risk stratification in well known phenotype

LQTc Syndrome




Risk stratification in well known phenotype

Laminopathies



Risk stratification in well known phenotype

Laminopathies



Usefulness of Cardiovascular Genetic

- Intermediate Phenotype
- Risk stratification of well known phenotype
- **Molecular Autopsy**
- Family Screening



Molecular Autopsy



Next generation sequencing

Exome sequencing

The exome (the protein-coding region of the human genome) represents less than 2% of the genetic code, but contains ~85% of known disease-related variants




46 Chromosomes




>3 billions base pairs

More than 20.000 genes coding for proteins




Next generation sequencing


Flow chart



Next generation sequencing Flow chart



Next generation sequencing Flow chart



Next generation sequencing

Flow chart

Pathogenic
Likely pathogenic
Variant of unknown significance
Benign




Usefulness of Cardiovascular Genetic


- Intermediate Phenotype
- Risk stratification of well known phenotype
- Molecular Autopsy
- **Family Screening**

Genome wide association study

Chr 9 genetic variants and risk of MI




A
WTCCC study




B
German MI
Family study

Chromosome

9p21.3 chromosomal region




Risk of chromosome 9p21 locus compared with conventional risk factors




9p21.3 genetic variants in early-onset myocardial infarction

Angiographic endpoint

rs1333040




Chromosomal location of coronary artery disease genes



Cardiovascular genetic Genetic Risk Score

Hazard ratio 2.32 (1.25-4.35), P = 0.008



European Heart Journal Advance Access published April 23, 2015

European Heart Journal
doi:10.1093/eurheartj/ehv106

CLINICAL RESEARCH
Coronary artery disease

Predicting sudden cardiac death using common genetic risk variants for coronary artery disease

Jussi A. Hernesniemi^{1,2*}, Leo-Pekka Lyytikäinen¹, Niku Oksala^{1,3}, Ilkka Seppälä¹, Marcus E. Kleber⁴, Nina Mononen¹, Winfried März^{4,5,6}, Jussi Mikkelsen^{7,8}, Tanja Pessi^{7,9}, Anne-Mari Louhelainen⁷, Mika Martiskainen⁷, Kjell Nikus¹⁰, Norman Klopp^{11,12}, Melanie Waldenberger^{11,12}, Thomas Illig^{11,12,14}, Mika Kähönen¹⁵, Reijo Laaksonen¹, Pekka J. Karhunen²¹, and Terho Lehtimäki¹¹

TAKE HOME MESSAGES

- La genetica cardiovascolare, essendo applicabile precocemente nella vita, è uno strumento potenzialmente ideale per prevenire la morte improvvisa
- La traduzione pratica di questa potenzialità è oggi possibile in clinica ma resta ancora tecnicamente molto complessa
- Occorre fare riferimento ad un team multidisciplinare con competenze ultraspecialistiche (Cardiologo, Genetista, Psicologo)
- La genetica della SCD applicata alla cardiopatia ischemica rappresenta il futuro

